Source | Total no. of patients | Main reason for hypoxemic respiratory failure (main baseline risk factor) | Main exposure | Comparator | P/F ratio (mean) | Outcomes of interest assessed |
---|---|---|---|---|---|---|
Wysocki [27] 1995 | 41 | Mixed AHRF (CAP 39.0%, CPE 34.1%) | NIV (n = 21) | SOT (n = 20) | 207 | Mortality, intubation |
Antolnelli [26] 1998 | 64 | Mixed AHRF (CPE 19%, atelectasis 25%) | NIV (n = 32) | IMV (n=32) | 120 | Mortality |
Confalonieri [29] 1999 | 56 | CAP | NIV (n = 28) | SOT (n = 28) | 175 | Mortality, intubation |
Antonelli [28] 2000 | 40 | Mixed AHRF (ARDS 37.5%, atelectasis 25%) | NIV (n = 20) | SOT (n = 20) | NA | Mortality, intubation |
Delcaux [30] 2000 | 123 | Mixed AHRF (CAP 54.5%) | NIV (n = 62) | SOT (n = 61) | 144 | Mortality, intubation |
Martin [32] 2000 | 61 | Mixed AHRF (COPD 38%) | NIV (n = 32) | SOT (n = 29) | 199 | Mortality, intubation |
Hilbert [31] 2001 | 52 | CAP in immunocompromised patients | NIV (n = 26) | SOT (n = 26) | 139 | Mortality, intubation |
Ferrer [34] 2003 | 105 | Mixed AHRF (CAP 32.4%, CPE 28.6%) | NIV (n = 51) | SOT (n = 54) | 103 | Mortality, intubation |
Cosentini [33] 2010 | 47 | CAP | NIV (n = 20) | SOT (n = 27) | 248 | Mortality, intubation |
Squadrone [35] 2010 | 40 | Mixed AHRF in immunocompromised patients | NIV (n = 20) | SOT (n = 20) | 269 | Mortality, intubation |
Wermke [37] 2012 | 86 | CAP in immunocompromised patients | NIV (n = 42) | SOT (n = 44) | 270 | Mortality, intubation |
Zhan [38] 2012 | 40 | ALI (immunocompromised 30%) | NIV (n = 21) | SOT (n = 19) | 230 | Mortality, intubation |
Brambilila [36] 2014 | 81 | CAP (immunocompromised 32%) | NIV (n = 40) | SOT (n = 41) | 141 | Mortality, intubation |
Azevedo [39] 2015 | 30 | CPE (43.3%), CAP (33.3%) | NIV (n=16) | HFNO (n=14) | NA | Intubation |
Frat [12] 2015 | 310 | Mixed ARF (CAP 63.5%) | NIV (n = 110) |
HFNO (n = 106) SOT (n = 94) | 155 | Mortality, intubation |
Lamiale [40] 2015 | 100 | Mixed AHRF in immunocompromised patients (sepsis related 50%) | HFNO (n = 52) | SOT (n = 48) | 114 | Intubation |
Lemiale [41] 2015 | 374 | Pneumonia in immunocompromised patients | NIV (n = 191) | SOT (n = 183) | 142 | Mortality, intubation |
Jones [43] 2016 | 303 | Mixed AHRF (COPD 23.9%, Pneumonia 23.8%) | HFNO (n = 165) | SOT (n = 138) | NA | Mortality, intubation |
Muncharaz [42] 2017 | 65 | Mixed AHRF (CAP 63.1%) | NIV (n = 34) | IMV (n = 31) | 97 | Mortality |
Azoulay [25] 2018 | 776 | Mixed AHRF in immunocompromised patients (Pneumonia 53.0%) | HFNO (n = 388) | SOT (n = 388) | 132 | Mortality, intubation |
He [44] 2019 | 200 | CAP | NIV (n = 102) | SOT (n = 98) | 231 | Mortality, intubation |
Andino [45] 2020 | 46 | Mixed AHRF (CAP 30%) | HFNO (n = 24) | SOT(n=22) | 96 | Mortality, intubation |
AlptekİnoĞlu Mendİl [46] 2021 | 100 | Mixed AHRF (pneumonia 74%) | HFNO (n = 51) | SOT(n=49) | 262 | Mortality, intubation |
Awadallah [47] 2021 | 52 | ARDS | NIV (n = 26) | IMV (n = 26) | 95 | Mortality |
Grieco [48] 2021 | 109 | AHRF in COVID-19 patients | NIV (n = 54) | HFNO (n = 55) | 102 | Mortality, intubation |